The Aesthetic Society Year in Review 2023/2024

This year's cruise was our largest since 2007, with more than 150 cabins sold and over 320 attendees, including spouses, families, and guests. Among them were 120 registered plastic surgeons, including 15 current and past leaders of both the Society and Foundation. Our faculty featured 37 distinguished subject matter experts, eight of whom were first-time cruise speakers, and attendees represented ten different countries.

This is my last newsletter as President of The Aesthetic Foundation, and it has been a busy and productive year. Our core mission is to support research that is relevant to practicing plastic surgeons and improve the safety and effectiveness of the procedures that we offer to our patients.

Spring is just around the corner, and The Aesthetic Society is already experiencing renewed energy and new growth. I wanted to answer some questions about what’s next.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.”

The dues support the 30+ ongoing studies that have been funded by The Foundation including studies such as “Cytotoxicity of Implant-Exposed Serum on Breast Cancer”, “Impact of Xeomin, Dysport, and Botox on Nerve Injuries”, “Effect of Intramuscular Fat Grafting on New Muscle Formation”, “Does TXA reduce Bruising After Hyaluronic Acid Filler Injection: A Prospective half face study”, “Increasing SMAS Durability via Photochemical Passivation for Facelifts”, and “Histologic Effects of Energy-Based Skin Tightening Treatments”.